2. Signaling Pathways
  3. Neuronal Signaling
  4. Glucosylceramide Synthase (GCS)
  5. Glucosylceramide Synthase (GCS) Inhibitor

Glucosylceramide Synthase (GCS) Inhibitor

Glucosylceramide Synthase (GCS) Inhibitors (27):

Cat. No. Product Name Effect Purity
  • HY-14885
    Eliglustat
    		Inhibitor 99.74%
    Eliglustat is an specific, potent and orally active glucocerebroside synthase inhibitor with an IC50 of 24 nM.
  • HY-17020
    Miglustat
    		Inhibitor 99.95%
    Miglustat (N-Butyldeoxynojirimycin) is an orally active and reversible ceramide glucosyltransferase inhibitor. Miglustat can be used for the research of type I gaucher disease.
  • HY-14885A
    Eliglustat hemitartrate
    		Inhibitor 99.27%
    Eliglustat hemitartrate is an specific, potent and orally active glucocerebroside synthase inhibitor with an IC50 of 24 nM.
  • HY-17020A
    Miglustat hydrochloride
    		Inhibitor 99.97%
    Miglustat (N-Butyldeoxynojirimycin) hydrochloride is an orally active and reversible ceramide glucosyltransferase inhibitor, with blood-brain barrier permeability. Miglustat hydrochloride can be used for the research of type I gaucher disease.
  • HY-206259
    CCG-203586
    		Inhibitor
    CCG-203586 is a brain-penetrant glucosylceramide synthase (GCS) inhibitor. CCG-203586 reduces GCS production and brain levels, blocks the first committed step in ganglioside biosynthesis, and lowers downstream ganglioside levels. CCG-203586 can be used for the research of Tay-Sachs, Sandhoff disease, and types 2 and 3 Gaucher disease.
  • HY-186121A
    Glucosylceramide synthase-IN-6
    		Inhibitor
    Glucosylceramide synthase-IN-6 (G3-3B) is a glucosylceramide synthase (GCS) inhibitor that can be used for the study of the diseases and disorders associated with GCS activity, such as lysosomal storage disorders.
  • HY-186121
    Glucosylceramide synthase-IN-5
    		Inhibitor
    Glucosylceramide synthase-IN-5 (G3-3) is a glucosylceramide synthase (GCS) inhibitor that can be used for the study of the diseases and disorders associated with GCS activity, such as lysosomal storage disorders.
  • HY-12744
    Genz-123346 free base
    		Inhibitor 99.57%
    Genz-123346 free base is an orally available inhibitor of glucosylceramide synthase. Genz-123346 blocks the conversion of ceramide to glucosylceramide (GL1) and inhibits GM1 with an IC50 of 14 nM.
  • HY-116392D
    PDMP hydrochloride
    		Inhibitor 99.9%
    PDMP hydrochloride is a glucosylceramide synthase (GCS) inhibitor. PDMP hydrochloride induces apoptosis in K562/A02 cells. PDMP hydrochloride can be used in cancer (such as leukemia) research.
  • HY-116392B
    DL-threo-PDMP hydrochloride
    		Inhibitor 99.40%
    DL-threo-PDMP hydrochloride is a competitive glucosylceramide synthase (GCS) inhibitor and antimalarial agent. DL-threo-PDMP hydrochloride competitively inhibits the activity of GCS. DL-threo-PDMP hydrochloride restores cisplatin sensitivity in cisplatin-resistant testicular germ cell tumor cells. DL-threo-PDMP hydrochloride blocks the growth of ring-stage Plasmodium falciparum parasites.
  • HY-N1938
    D(+)-Raffinose pentahydrate
    		Inhibitor 98.0%
    D(+)-Raffinose pentahydrate is an orally active inhibitor of LecA (Kd = 32 μM) and GtfC. D(+)-Raffinose pentahydrate reduces cyclic diguanylate (c-di-GMP) by increased activity of a c-di-GMP specific phosphodiesterase. D(+)-Raffinose pentahydrate interferes with GTF function. D(+)-Raffinose pentahydrate decreases IL-4 and IL-5 mRNA. D(+)-Raffinose pentahydrate exhibits biofilm-inhibitory activity against Pseudomonas aeruginosa and Streptococcus mutans and inhibits allergic airway eosinophilia.
  • HY-114615
    AMP-Deoxynojirimycin
    		Inhibitor 99.7%
    AMP-Deoxynojirimycin (AMP-DNM) is a potent ceramide glucosyltransferase and GCase 2 inhibitor. AMP-Deoxynojirimycin also is a GlcCer biosynthesis inhibitor.
  • HY-116392F
    D-threo-PDMP hydrochloride
    		Inhibitor 98.0%
    D-threo-PDMP hydrochloride is a potent glucoceramide synthase (GCS) inhibitor, which reduces the glycosphingolipids (such as GM3 and GD3) on the cell surface by inhibiting glycosylation, reduces the total length of the axon plexus and the number of axon branch points, and inhibits neurite growth. D-threo-PDMP hydrochloride inhibits the synthesis of GM3, thereby reducing the adhesion ability of B16 melanoma cells and mimicking the pathological effects of hyperglycemia/TGF-β1. D-threo-PDMP hydrochloride inhibits the synthesis of GD3, thereby protecting liver cells from apoptosis induced by TNF-α. D-threo-PDMP hydrochloride can be used to study diseases related to targeted glycosphingolipid metabolism.
  • HY-116392H
    D,L-erythro-PDMP hydrochloride
    		Inhibitor 98.45%
    D,L-erythro-PDMP hydrochloride is an erythro isomer of PDMP. D,L-erythro-PDMP hydrochloride causes growth inhibition of cultured rabbit skin fibroblasts. PDMP is an effective inhibitor of UDP-glucose:ceramide glucosyltransferase.
  • HY-155715
    G43
    		Inhibitor 99.76%
    G43 is a potent, selective glucosyltransferase inhibitor, with the Kd of 3.7μM and 46.9 nM for GtfB and GtfC, respectively. G43 has antibacterial to S. mutans in vitro and in vivo, and can be used for dental caries study.
  • HY-116392E
    D-threo-PDMP
    		Inhibitor 99.50%
    D-threo-PDMP is a potent glucoceramide synthase (GCS) inhibitor, which reduces the glycosphingolipids (such as GM3 and GD3) on the cell surface by inhibiting glycosylation, reduces the total length of the axon plexus and the number of axon branch points, and inhibits neurite growth. D-threo-PDMP inhibits the synthesis of GM3, thereby reducing the adhesion ability of B16 melanoma cells and mimicking the pathological effects of hyperglycemia/TGF-β1. D-threo-PDMP inhibits the synthesis of GD3, thereby protecting liver cells from apoptosis induced by TNF-α. D-threo-PDMP can be used to study diseases related to targeted glycosphingolipid metabolism.
  • HY-155716
    G43-C3-TEG
    		Inhibitor
    G43-C3-TEG is a glycosyl-transferase inhibitor. G43-C3-TEG reduces the biofilm formation by decreasing the production of EPS (extracellular polysaccharides).
  • HY-14885R
    Eliglustat (Standard)
    		Inhibitor
    Eliglustat (Standard) is the analytical standard of Eliglustat. This product is intended for research and analytical applications. Eliglustat is an specific, potent and orally active glucocerebroside synthase inhibitor with an IC50 of 24 nM.
  • HY-156208
    C2 Adamantanyl galactosylceramide (d18:1/2:0)
    		Inhibitor
    C2 Adamantanyl galactosylceramide (AdaGalCer) (d18:1/2:0) is a bioactive sphingolipid. C2 Adamantanyl galactosylceramide (d18:1/2:0) stimulates glucocerebrosidase activity in vitro. C2 Adamantanyl galactosylceramide (d18:1/2:0) inhibits microsomal LacCer and Gb3 synthase, and inhibits cell sulfatide synthesis. C2 Adamantanyl galactosylceramide (d18:1/2:0) reduces glucosylceramide (GlcCer) levels in normal and lysosomal storage disease (LSD) cells. C2 Adamantanyl galactosylceramide (d18:1/2:0) acts as a substrate for A4GALT and is able to lower Gb3 levels with an IC50 concentration of 40 μM in fabry disease cells.
  • HY-181989
    CAIF
    		Inhibitor
    CAIF is an irreversible, selective allosteric covalent inhibitor of ucosyltransferase 8 (FUT8) with an IC50 of 5.7 μM. CAIF inhibits core fucosylation modification in cancer cells, and suppresses the invasion and migration of cancer cells. CAIF is applicable for cancer research.